ArticleThe Journal of clinical investigation2006
Differential exoprotease activities confer tumor-specific serum peptidome patterns.
Article in The Journal of clinical investigation, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01604798 (Serum Proteomic Profiling for the Early Diagnosis of Colorectal Cancer), which is not on this map. Cited by 216 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Serum Proteomic Profiling for the Early Diagnosis of Colorectal Cancer
Who cites it
216 citing papers in PubMed, 1 synthesis or guideline pooled it, 748 citations in OpenAlex.
- Mass spectrometry-based serum and plasma peptidome profiling for prediction of treatment outcome in patients with solid malignancies.The oncologist · 2014Pooled it
- Exploratory study on application of MALDI‑TOF‑MS to detect serum and urine peptides related to small cell lung carcinoma.Molecular medicine reports · 2020Trial
- Distinguishing neurocysticercosis epilepsy from epilepsy of unknown etiology using a minimal serum mass profiling platform.Experimental parasitology · 2018Trial
- [Detection of Serum Peptides in Patients with Lung Squamous Cell Carcinoma by MALDI-TOF-MS and Analysis of Their Correlation with Chemotherapy Efficacy].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2017Trial
- Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2010Trial
- A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden.BMC medicine · 2008Trial
- Development and validation of a serum peptidomic signature for early detection of asymptomatic ovarian cancer: A multi-center prospective study.Cell reports. Medicine · 2026Article
- Degradation graphs reveal hidden proteolytic activity in peptidomes.PLoS computational biology · 2026Article
- Mechanistic Insights into Tumorigenesis from Serum Proteins.medRxiv : the preprint server for health sciences · 2025Article
- Kinin Receptors B1 and B2 Mediate Breast Cancer Cell Migration and Invasion by Activating the FAK-Src Axis.International journal of molecular sciences · 2024Article
- Comparison of Peptidomes Extracted from Healthy Tissue and Tumor Tissue of the Parotid Glands and Saliva Samples.International journal of molecular sciences · 2024Article
- Article
- Correlation between small-cell lung cancer serum protein/peptides determined by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and chemotherapy efficacy.Clinical proteomics · 2024Article
- Description of an activity-based enzyme biosensor for lung cancer detection.Communications medicine · 2024Article
- Involvement of CCCTC-binding factor in epigenetic regulation of cancer.Molecular biology reports · 2023Review
- MALDI-TOF MS Analysis of Serum Peptidome Patterns in Cervical Cancer.Biomedicines · 2023Article
- Protein Biomarker Discovery Studies on Urinary sEV Fractions Separated with UF-SEC for the First Diagnosis and Detection of Recurrence in Bladder Cancer Patients.Biomolecules · 2023Article
- Kinin BScientific reports · 2023Article
- Parallelization with Dual-Trap Single-Column Configuration Maximizes Throughput of Proteomic Analysis.Analytical chemistry · 2022Article
- Circulating SOD2 Is a Candidate Response Biomarker for Neoadjuvant Therapy in Breast Cancer.Cancers · 2022Article
156 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
15 authors at 1 institution in 1 country.
Funding
Abstract
Recent studies have established distinctive serum polypeptide patterns through mass spectrometry (MS) that reportedly correlate with clinically relevant outcomes. Wider acceptance of these signatures as valid biomarkers for disease may follow sequence characterization of the components and elucidation of the mechanisms by which they are generated. Using a highly optimized peptide extraction and matrix-assisted laser desorption/ionization-time-of-flight (MALDI-TOF) MS-based approach, we now show that a limited subset of serum peptides (a signature) provides accurate class discrimination between patients with 3 types of solid tumors and controls without cancer. Targeted sequence identification of 61 signature peptides revealed that they fall into several tight clusters and that most are generated by exopeptidase activities that confer cancer type-specific differences superimposed on the proteolytic events of the ex vivo coagulation and complement degradation pathways. This small but robust set of marker peptides then enabled highly accurate class prediction for an external validation set of prostate cancer samples. In sum, this study provides a direct link between peptide marker profiles of disease and differential protease activity, and the patterns we describe may have clinical utility as surrogate markers for detection and classification of cancer. Our findings also have important implications for future peptide biomarker discovery efforts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.